Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Treatment of antipsychotic-induced parkinsonism in schizophrenic patients

https://doi.org/10.14412/2074-2711-20214-4-11

Full Text:

Abstract

Antipsychotic-induced parkinsonism (AIP) is one of the prognostically unfavorable complications of psychopharmacotherapy in patients with schizophrenia. Many studies have investigated various drugs that are used to treat this neurological side effect. This review analyzes drugs that are used and may be perspective for the treatment of AIP. We searched for full-text publications in Russian and English in the following databases: E-Library, PubMed, Web of Science, Springer, using keywords and combined word searches over the past decade (2011—2020). The review covers drugs that are promising for the correction of AIP, including anticholinergic drugs; NMDA receptor antagonists; dopamine receptor agonists; selective inhibitors of monoamine oxidase B; catecholamine transferase inhibitors; melatonin preparations; melatonin receptor agonists; benzodiazepines; herbal preparations traditionally used for the prevention and correction of extrapyramidal syndrome of various etiologies. Currently, a small number of medications are used in clinical practice for the treatment of AIP. However, not all of them are registered in the Russian Federation. Along with the differences in the mechanisms of AIP pathogenesis in specific patients, the limited choice of AIP treatments makes it difficult to solve the problem of adverse neurological complications of psychopharmacotherapy in schizophrenia.

About the Authors

E. E. Vaiman
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation

3, Bekhterev St., Saint Petersburg 192019.


Competing Interests:

There are no conflicts of interest.



N. A. Shnayder
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia; V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

3, Bekhterev St., Saint Petersburg 192019; 1, Partisan Zheleznyak St., Krasnoyarsk 660022.


Competing Interests:

There are no conflicts of interest.



N. G. Neznanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation

3, Bekhterev St., Saint Petersburg 192019.


Competing Interests:

There are no conflicts of interest.



R. F. Nasyrova
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia
Russian Federation

3, Bekhterev St., Saint Petersburg 192019.


Competing Interests:

There are no conflicts of interest.



References

1. Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Drug-induced parkinsonism. Sotsial'naya i klinicheskaya psikhiatriya = Social and clinic psychiatry. 2021;31(1):96-103 (In Russ.).

2. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-7. doi: 10.1001/archpsyc.60.10.974

3. Scharrer J, Tatsch K, Schwarz J, et al. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand. 1994 Oct;90(4):266-8. doi: 10.1111/j.1600-0447.1994.tb01591.x

4. Al Hadithy AF, Wilffert B, Bruggeman R, et al. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol. 2009;24(2):123-8. doi: 10.1002/hup.997

5. Bakker PR, Bakker E, Amin N, et al. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One. 2012;7(5):e36561. doi: 10.1371/journal.pone.0036561

6. Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Diagnostic methods for drug-induced parkinsonism: a review of Russian and foreign literature. Sibirskiy vestnik psikhia-trii i narkologii = Siberian Herald of Psychiatry and Addiction Psychiatry. 2020;4(109):64-72. doi: 10.26617/1810-3111-2020-4(109)-64-72 (In Russ.).

7. Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999 Mar;20(3):269-75. doi: 10.2165/00002018-199920030-00006

8. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-9. doi: 10.1176/appi.ajp.158.3.360

9. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018;7(2):233-48. doi: 10.1007/s40120-018-0105-0

10. Branchey MH, Branchey LB, Richardson MAR. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry. 1981 May;138(5):608-12. doi: 10.1176/ajp.138.5.608

11. Shapiro AK. Psychochemotherapy. In: Grenell RO, Gabay S, editors. Biological foundations of psychiatry. New York: Raven Press; 1971. P. 793-840.

12. Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry. 1997 Oct;21(7):1059-94. doi: 10.1016/s0278-5846(97)00099-7

13. Pierre J. Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management. Drug Saf. 2005;28(3):191-208. doi: 10.2165/00002018-200528030-00002

14. Nasyrova RF, Neznanov NG, editors. Klinicheskaya psikhofarmakogenetika [Clinical psychopharmacogenetics]. St. Petersburg: DEAN Publishing House; 2019. 405 p. (In Russ.).

15. Nasyrova RF, Schnaider NA, Mironov KO, et al. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):88-93. doi: 10.14412/2074-2711-2018-4-88-93 (In Russ.).

16. Haase HJ. Clinical observations on the actions of neuroleptics. In: Haase HJ, Janssen PA, editors. The actions of neuroleptic drugs: a psychiatric, neurological, and pharmacological investigation. Amsterdam: N Holland; 1965. P. 1-98.

17. Singh M. Therapeutic reversal with benztropine in schizophrenia. J Nerv Ment Dis. 1975 Apr;160(4):258-66. doi: 10.1097/00005053-197504000-00005

18. Johnston EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med. 1983 Aug;13(3):513-27. doi: 10.1017/s0033291700047942

19. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22(1):254-9.

20. Ungvari GS, Chiu HFK, Lam LCW, et al. Gradual withdrawal of long-term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol. 1999 Apr;19(2):141-8. doi: 10.1097/00004714-199904000-00009

21. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17(5):363-84. doi: 10.2165/00002512-200017050-00004

22. Di Mascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976 May;33(5):599-602. doi: 10.1001/archpsyc.1976.01770050055008

23. Aoki F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988 Jan;14(1):35-51. doi: 10.2165/00003088-198814010-00003

24. Gianutsos G, Stewart C, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985 Apr 16;110(3):357-61. doi: 10.1016/0014-2999(85)90564-3

25. Yadalam KG. Drug-induced parkinsonism. In: Keshavan MS, Kennedy JS, editors. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; 1992. P. 119-29.

26. Yaryura-Tobias JA, Wolpert A, Dana L, et al. Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst. 1970 Jan;31(1):60-3.

27. Rajput A, Rozdilsky B, Hornykiewicz O, et al. Reversible drug induced parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982 Oct;39(10):644-6. doi: 10.1001/archneur.1982.00510220042009

28. Di Fabio R, De Filippis S, Cafariello C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism. Clin Neuropharmacol. 2013;36(5):162-5. doi: 10.1097/WNF.0b013e3182a2ce3f

29. Weng JJ, Wang LH, Zhu H, et al. Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. Neuropsychiatr Dis Treat. 2019 Aug 7;15:2195-203. doi: 10.2147/NDT.S205933. eCollection 2019.

30. Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacoki-netic/pharmacodynamic, randomized, doubleblind study. Mov Disord. 2005;20(7):803-9. doi: 10.1002/mds.20400

31. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016;30(8):703-17. doi: 10.1007/s40263-016-0360-5

32. VIDAL. Available from: https://www.vidal.ru/drugs/molecule/2081 (accessed 13.04.2021).

33. Verbitsky EV. Psychotropic properties of melatonin drugs in experiment and clinic. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2019;15(44):32-40. doi: 10.33978/2307-3586-2019-15-44-32-40 (In Russ.).

34. Sood S. Melatonin and sleep in schizophrenia: a commentary. Sleep Med Dis Int J. 2018;2(4):93-4. doi: 10.15406/smdij.2018.02.00049

35. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113-9. doi: 10.1007/s11011-012-9307-9

36. Morera-Fumero AL, Abreu-Gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci. 2013;14(5):9037-50. doi: 10.3390/ijms14059037

37. Gobbi G, Comai S. Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep. Front Endocrinol. 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. eCollection 2019.

38. Mutschler J, Rusch N, Schonfelder H, et al. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacol Bull. 2012 Feb 15;45(1):35-43.

39. Englisch S, Jung HS, Eisenacher S, et al. Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study. J Clin Psychopharmacol. 2018;38(4):357-61. doi: 10.1097/JCP.0000000000000909

40. Mishra A, Maiti R, Mishra BR, et al. Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. Eur Neuropsychopharmacol. 2020;31:109-18. doi: 10.1016/j.euroneuro.2019.11.008

41. Hatta K, Kishi Y, Wada K, et al. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors. J Clin Psychiatry. 2019 Dec 17;81(1):19m12865. doi: 10.4088/JCP.19m12865

42. Skelton RL, Kornhauser JM, Tate BA. Personalized medicine for pathological circadian dysfunctions. Front Pharmacol. 2015 Jun 19;6:125. doi: 10.3389/fphar.2015.00125. eCollection 2015.

43. Laudon М, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014 Sep 9;15(9):15924-50. doi: 10.3390/ijms150915924

44. Spadoni G, Bedim A, Rivara S, Mor М. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17(6):733-41. doi: 10.1111/j.1755-5949.2010.00197.x

45. Farver DK, Khan МН. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother. 2001;35(4):435-7. doi: 10.1345/aph.10214

46. Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson's disease. Lancet. 1997 Apr 26;349(9060):1222-3. doi: 10.1016/S0140-6736(05)62416-6

47. Lloyd GK, Lowenthal A, Javoy-Agid F, Constantidinis J. GABAA receptor complex function in frontal cortex membranes from control and neurological patients. Eur J Pharmacol. 1991 Мяу 2;197(1):33-9. doi: 10.1016/0014-2999(91)90361-s

48. Geoffrey YMW, Tarun B, Rohan D. Potential antipsychotic effects of zolpidem. Aust N Z J Psychiatry. 2010 Feb;44(2):190. doi: 10.3109/00048670903487290

49. Eslami-Shahrbabaki М, Barfeh B, Nasirian М. Persistent psychosis after abuse of high dose of zolpidem. Addict Health. Summer-Autumn 2014;6(3-4):159-62.

50. Saint-Clair Bahls. tolerance to zolpidem-induced hallucinations: case report. Rev Psiquiatr Rio Gd Sul. 2005;27(3):319-22. doi: 10.1590/S0101-81082005000300011

51. Stummer L, Markovic М, Maroney МЕ. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines (Basel). 2018;5(3):88. doi: 10.3390/medicines5030088

52. Ferentinos P, Paparrigopoulos Т. Zopiclone and sleepwalking. Int J Neuropsychopharmacol. 2009;12(1):141-2. doi: 10.1017/S1461145708009541

53. Kajimura N, Kato М, Okuma Т, Onuma Т. Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):477-90. doi: 10.1016/0278-5846(94)90005-1

54. Diaz GA, Costanzo МС, Rosas МЕ, Arroyo MB. Sleep Disorders in Schizophrenia. A Review of Literature. Theranostics Brain Spine Neural Disord. 2017;1(5):555575. doi: 10.19080/rBSND.2017.01.555575


For citation:


Vaiman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F. Treatment of antipsychotic-induced parkinsonism in schizophrenic patients. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):4-11. (In Russ.) https://doi.org/10.14412/2074-2711-20214-4-11

Views: 90


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)